TransCode's TTX-MC138 Shows Survival Benefit in Breast Cancer Bone Metastasis Model — TransCode Therapeutics, Inc.

Event summary

TransCode Therapeutics published preclinical study results showing TTX-MC138 significantly improved survival in breast cancer bone metastasis model.
TTX-MC138 demonstrated favorable tolerability with no observed systemic toxicity in repeated dosing.
Study led by Dr. Anna Moore, co-founder and Chair of TransCode's Scientific Advisory Board.
Results support potential applicability of miR-10b inhibition across multiple metastatic tumor types.
Phase 1a clinical trial for TTX-MC138 achieved primary safety endpoint in 2025.

The big picture

TransCode's results highlight the growing focus on targeting specific molecular drivers of metastasis, an area with significant unmet medical need. The study validates the company's approach of using image-guided oligonucleotide nanotechnology to inhibit miR-10b, potentially expanding its therapeutic reach beyond the current colorectal cancer focus. This positions TransCode in the competitive landscape of RNA-based cancer therapeutics, where precision targeting of metastatic pathways is becoming increasingly important.

What we're watching

Clinical Translation: Whether these preclinical results will translate to human trials, particularly in breast cancer bone metastasis.
Pipeline Expansion: The pace at which TransCode can expand TTX-MC138's application to other metastatic tumor types.
Competitive Positioning: How this data positions TransCode against other companies developing metastasis-targeting therapies.